

Patient Agreement to Systemic Therapy: Consent Form	
Alectinib	
Patient's details / addressograph:	<input type="checkbox"/> Male <input type="checkbox"/> Female
	Special requirements (e.g. other language/other communication method)
	Consultant:

Name of proposed course of treatment:**Alectinib**

Tablets taken by mouth twice daily continuously

Treatment is supplied every 28 days

Treatment continued at the discretion of the treating doctor

Macmillan/CRUK leaflet given

Statement of health professional (to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in consent policy)

- I have discussed what the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, follow-up appointments) and location.

The intended benefits

- Curative – to give you the best possible chance of being cured
- Palliative – the aim is not to cure but to control or shrink the disease. The aim is to improve both quality of life and survival
- Adjuvant – therapy given after surgery to reduce the risk of recurrence of cancer
- Neo-adjuvant – therapy given to shrink the cancer before surgery or radiotherapy

Significant, unavoidable or frequently occurring risks:

Common side-effects: constipation or diarrhoea, fluid gain (watch for weight gain, ankle swelling, or swelling around the eyes), aching or pain in muscles, skin rash or skin sensitivity to the sun, harmless changes in vision, feeling sick (nausea) and being sick (vomiting), anaemia and tiredness, changes in your liver leading to disturbance of liver blood tests

Less common but potentially life threatening side-effects:

breathing problems; you may suddenly become breathless or your breathing may worsen, possibly with a cough or high temperature – you must tell your doctor straight away if you have any of these symptoms, it may mean you have an inflammation of the lungs (interstitial lung disease)

an abnormally slow heartbeat, leading to dizziness or fainting

Cancer can increase your risk of developing a blood clot (thrombosis), and having anti-cancer drug treatment may increase this risk further. A blood clot may cause pain, redness and swelling in a leg, or breathlessness and chest pain - you must tell your doctor straight away if you have any of these symptoms.

Alectinib may damage the development of a baby in the womb (fetus), leading to the many risks associated with an abnormal pregnancy. Therefore, I have discussed the issues of protected sex. This is an issue for both men and women. The patient has been advised not to become pregnant / not to get a partner pregnant during the period of treatment and for at least 3 months after completing treatment.

Any other risks:

.....

Clinician Signature	
Signed.....	Date
Full Name (print) /	Job Title.....
(Forename)	(Surname)

Statement of patient

Patient Signature	
Please read this form carefully, which describes the benefits and risks of the proposed treatment. You have the right to change your mind at any time, including after you have signed this form.	
I agree to undergo chemotherapy. I understand the treatment and am aware of the potential side-effects arising from this treatment.	
I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate training and experience.	
Signed.....	Name.....
Date.....	
A witness should sign below if the patient is unable to sign but has indicated his or her consent.	
Signature	Date
Name (PRINT)	

Statement of interpreter (where appropriate)

I have interpreted the information above to the patient to the best of my ability and in a way in which I believe s/he can understand.

Signed Date

Name (PRINT)

Copy accepted by patient: yes/no (please ring)
Copy to be retained in patient's notes

Reason for Update: N/A	Checked and approved by Consultant: Dr A Mehta
Version: 1	Date: 12.10.17